Nurix Therapeutics Shares Are Trading Higher After the Company Announced It Will Present Its Phase 1 Clinical Trial Cancer Data for BTK Degrader NX-5948.

BenzingaDec 2 21:43

Nurix Therapeutics Announces Webcast To Review New Data From Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

GlobeNewswireDec 2 20:00

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswireNov 25 20:00

Sector Update: Health Care Stocks Rise Pre-Bell Thursday

MT NewswiresNov 21 22:13

Nurix Therapeutics Receives PRIME Designation From the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

GlobeNewswireNov 21 05:00

Express News | Nurix Therapeutics Receives Prime Designation From the European Medicines Agency for Nx-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

BreakingsNov 21 05:00